Neurocognitive Risk With PCSK9 Inhibitors

被引：3
|
作者：
Khan, Abdur Rahman [1 ]
Riaz, Haris [1 ]
Farid, Talha [1 ]
Bolli, Roberto [1 ]
机构：
[1] Univ Louisville, Dept Med, Div Cardiovasc Med, 200 Abraham Flexner Way, Louisville, KY 40202 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2017年 / 69卷 / 19期
基金：
美国国家卫生研究院;
关键词：
CARDIOVASCULAR EVENTS; REDUCING LIPIDS; SAFETY; ALIROCUMAB; EFFICACY;
D O I：
10.1016/j.jacc.2017.02.063
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2468 / 2469
页数：3
相关论文
共 50 条
  • [31] PCSK9 inhibitors: smooth sailing or a little turbulence ahead?
    Hegele, Robert A.
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (07) : 490 - 492
  • [32] Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
    Koskinas, Konstantinos C.
    Wilhelm, Matthias
    Windecker, Stephan
    SWISS MEDICAL WEEKLY, 2016, 146 : w14333
  • [33] Familial hypercholesterolaemia: PCSK9 inhibitors are coming
    Santos, Raul D.
    Watts, Gerald F.
    LANCET, 2015, 385 (9965) : 307 - 310
  • [34] PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention
    Marco-Benedi, Victoria
    Sanchez-Hernandez, Rosa M.
    Diaz, Jose Luis
    Jarauta, Estibaliz
    Suarez-Tembra, Manuel
    Pinto, Xavier
    Morillas, Carlos
    Plana, Nuria
    Pedro-Botet, Juan
    Civeira, Fernando
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [35] A New Approach to PCSK9 Therapeutics
    Wang, Nan
    Tall, Alan R.
    CIRCULATION RESEARCH, 2017, 120 (07) : 1063 - 1065
  • [36] Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association
    Orringer, Carl E.
    Jacobson, Terry A.
    Saseen, Joseph J.
    Brown, Alan S.
    Gotto, Antonio M.
    Ross, Joyce L.
    Underberg, James A.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2017, 11 (04) : 880 - 890
  • [37] PCSK9 Inhibitors The Magic Bullet for LDL Cholesterol Reduction?
    Richter, Kurt
    Barthel, Andreas
    Bornstein, Stefan R.
    El-Armouche, Ali
    Wagner, Michael
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2016, 141 (12) : 863 - U181
  • [38] PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
    Jia, Xiaoming
    Al Rifai, Mahmoud
    Saeed, Anum
    Ballantyne, Christie M.
    Virani, Salim S.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2022, 18 : 555 - 566
  • [39] Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk
    Ballve Behr, Paulo Eduardo
    Moriguchi, Emilio Hideyuki
    Castro, Iran
    Bodanese, Luiz Carlos
    Dutra, Oscar Pereira
    Leaes, Paulo Ernesto
    Pimentel Filho, Pedro
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2018, 111 (01) : 104 - 107
  • [40] Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors
    Safarova, Maya S.
    Kullo, Iftikhar J.
    ATHEROSCLEROSIS, 2022, 361 : 30 - 31
12345